Compare FR & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FR | KNSA |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 7.7B |
| IPO Year | 1996 | 2018 |
| Metric | FR | KNSA |
|---|---|---|
| Price | $54.65 | $94.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 7 |
| Target Price | $64.38 | ★ $111.57 |
| AVG Volume (30 Days) | ★ 1.8M | 883.3K |
| Earning Date | 10-21-2026 | 10-27-2026 |
| Dividend Yield | ★ 3.64% | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | ★ 1.66 | 1.14 |
| Revenue | ★ $727,076,000.00 | $677,564,000.00 |
| Revenue This Year | $8.45 | $54.80 |
| Revenue Next Year | $6.13 | $28.50 |
| P/E Ratio | ★ $33.11 | $82.69 |
| Revenue Growth | 8.58 | ★ 60.09 |
| 52 Week Low | $53.27 | $37.02 |
| 52 Week High | $69.88 | $99.31 |
| Indicator | FR | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 37.10 | 57.19 |
| Support Level | $53.27 | $87.30 |
| Resistance Level | $64.27 | $98.90 |
| Average True Range (ATR) | 0.95 | 4.44 |
| MACD | 0.20 | -0.19 |
| Stochastic Oscillator | 39.19 | 58.03 |
First Industrial Realty Trust Inc is a real estate investment trust that owns, manages, acquires, sells, develops, and redevelops industrial real estate. Through its fully integrated operating and investing platform, the company provides facilities and customer service to multinational corporations and regional firms that are essential for their supply chains. The company serves a diverse tenant base across various sectors, including e-commerce, logistics, transportation, manufacturing, retail, consumer services, food and beverage, building materials, wholesale goods, health services, and government.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.